The Affiliated Suzhou Hospital of Nanjing Medical University.
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.
Anticancer Drugs. 2020 Nov;31(10):1012-1017. doi: 10.1097/CAD.0000000000000925.
Tumor cells can activate platelets, which in turn facilitate tumor cell survival and dissemination. Platelets inhibition or blocking platelet-tumor cell interactions has become a strategy to suppress tumor progression. In this study, we investigated the effect of ticagrelor, a new antiplatelet drug, on tumor cell proliferation and metastasis. Our results show that ticagrelor not only inhibits the proliferation, migration, and invasion of B16F10 and Lewis lung carcinoma cells but also induces platelet apoptosis. In addition, we find that apoptosis of the platelet cells is dose dependent. Further, the result of in-vivo experiments proved that ticagrelor treatment decreased the tumor metastasis. The results of this study demonstrate that ticagrelor may be a potential anti-tumor agent for tumor metastasis.
肿瘤细胞可以激活血小板，而血小板反过来又促进肿瘤细胞的存活和扩散。抑制血小板或阻断血小板与肿瘤细胞的相互作用已成为抑制肿瘤进展的一种策略。在这项研究中，我们研究了新型抗血小板药物替格瑞洛对肿瘤细胞增殖和转移的影响。我们的结果表明，替格瑞洛不仅抑制 B16F10 和 Lewis 肺癌细胞的增殖、迁移和侵袭，还诱导血小板凋亡。此外，我们发现血小板细胞的凋亡是剂量依赖性的。此外，体内实验结果证明替格瑞洛治疗可减少肿瘤转移。这项研究的结果表明，替格瑞洛可能是一种用于肿瘤转移的潜在抗肿瘤药物。
